Logo of Invex Therapeutics (ASX:IXC)Latest Invex Therapeutics (ASX:IXC) News

Page 1
Page 1 of 3

Market Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Explorers led the strongest gains, while biotech, payments and gold producers suffered the biggest falls. Takeover bids, project funding and trial results drove sharp moves across the market.

Resources stayed busy, but investors punished companies with weak cash positions, delayed approvals or disappointing operating updates.
Logan Eniac
31 Oct 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Invex Lines Up $10m Raise to Fund Multiple Sclerosis Trial and Alzheimer’s Research

Invex Therapeutics has paired its proposed acquisition of Rekover Therapeutics with a $10 million equity raising to fund a Phase 2a multiple sclerosis study and its existing Exenatide programs. The biotech ended September with A$3.59 million in cash, with shareholder approval still required for the larger part of the transaction.
Ada Torres
30 Oct 2026

Invex Adds Multiple Sclerosis Trial to Exenatide Pipeline With $10m Raise

Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.
Ada Torres
26 Oct 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

Invex Therapeutics Reports $1.35M Loss as Alzheimer’s Research Intensifies

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.
Ada Torres
31 Aug 2026

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.
Logan Eniac
25 July 2026

Invex Therapeutics Expands Alzheimer’s Research Amid Rising R&D Spend and $4M Cash Reserve

Invex Therapeutics has broadened its preclinical Alzheimer's program with Tessara Therapeutics, while its cash reserves dipped to $4.02 million in Q4 FY26 amid increased research and administrative costs.
Ada Torres
23 July 2026

Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.
Logan Eniac
25 Apr 2026

Invex Therapeutics Advances Exenatide Research with New Alzheimer’s Model Data

Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.
Ada Torres
24 Apr 2026

Healthcare Wrap - Week 7 (9 Feb -> 13 Feb) 2026

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.
Logan Eniac
14 Feb 2026

Invex Therapeutics Doubles Half-Year Loss Amid Progress in Alzheimer’s Drug Research

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.
Ada Torres
12 Feb 2026